Recombinant Human ADC Protein, GST-tagged

• Cat.No.: ADC-319H
• Product Overview: Human ADC full-length ORF ( ABM86174.1, 1 a.a. - 460 a.a.) recombinant protein with GST-tag at N-terminal.

Specification

• Description: The protein encoded by this gene belongs to the antizyme inhibitor family, which plays a role in cell growth and proliferation by maintaining polyamine homeostasis within the cell. Antizyme inhibitors are homologs of ornithine decarboxylase (ODC, the key enzyme in polyamine biosynthesis) that have lost the ability to decarboxylase ornithine; however, retain the ability to bind to antizymes. Antizymes negatively regulate intracellular polyamine levels by binding to ODC and targeting it for degradation, as well as by inhibiting polyamine uptake. Antizyme inhibitors function as positive regulators of polyamine levels by sequestering antizymes and neutralizing their effect. This gene encodes antizyme inhibitor 2, the second member of this gene family. Like antizyme inhibitor 1, antizyme inhibitor 2 interacts with all 3 antizymes and stimulates ODC activity and polyamine uptake. However, unlike antizyme inhibitor 1, which is ubiquitously expressed and localized in the nucleus and cytoplasm, antizyme inhibitor 2 is predominantly expressed in the brain and testis and localized in the endoplasmic reticulum-golgi intermediate compartment. Recent studies indicate that antizyme inhibitor 2 is also expressed in specific cell types in ovaries, adrenal glands and pancreas, and in mast cells. The exact function of this gene is not known, however, available data suggest its role in cell growth, spermiogenesis, vesicular trafficking and secretion. Accumulation of antizyme inhibitor 2 has also been observed in brains of patients with Alzheimer's disease. There has been confusion in literature and databases over the nomenclature of this gene, stemming from an earlier report that a human cDNA clone (identical to ODCp/AZIN2) had arginine decarboxylase (ADC) activity (PMID:14738999). Subsequent studies in human and mouse showed that antizyme inhibitor 2 was devoid of arginine decarboxylase activity (PMID:19956990). Alternatively spliced transcript variants have been described for this gene. [provided by RefSeq, Sep 2014]
• Source: Wheat Germ
• Species: Human
• Tag: GST
• Molecular Mass: 77 kDa
• AA Sequence: MAGYLSESDFVMVEEGFSTRDLLKE LTLGASQATTDEVAAFFVADLGAIV RKHFCFLKCLPRVRPFYAVKCNSSP GVLKVLAQLGLGFSCANKAEMELVQ HIGIPASKIICANPCKQIAQIKYAA KHGIQLLSFDNEMELAKVVKSHPSA KMVLCIATDDSHSLSCLSLKFGVSL KSCRHLLENAKKHHVEVVGVSFHIG SGCPDPQAYAQSIADARLVFEMGTE LGHKMHVLDLGGGFPGTEGAKVRFE EIASVINSALDLYFPEGCGVDIFAE LGRYYVTSAFTVAVSIIAKKEVLLD QPGREEENGSTSKTIVYHLDEGVYG IFNSVLFDNICPTPILQKKPSTEQP LYSSSLWGPAVDGCDCVAEGLWLPQ LHVGDWLVFDNMGAYTVGMGSPFWG TQACHITYAMSRVAWEALRRQLMAA EQEDDVEGVCKPLSCGWEITDTLCV GPVFTPASIM
• Applications: Enzyme-linked Immunoabsorbent Assay
  Western Blot (Recombinant protein)
  Antibody Production
  Protein Array
• Notes: Best use within three months from the date of receipt of this protein.
• Storage: Store at -80 centigrade. Aliquot to avoid repeated freezing and thawing.
• Storage Buffer: 50 mM Tris-HCI, 10 mM reduced Glutathione, pH=8.0 in the elution buffer.

Gene Information

• Gene Name: ADC arginine decarboxylase [ Homo sapiens ]
• Official Symbol: ADC
• Synonyms: AZI2; ODC-p; ODC1L
• Gene ID: 113451
• mRNA Refseq: NM_052998.2
• Protein Refseq: NP_443724.1
• MIM: 608353
• UniProt ID: Q96A70

Q&As

How does ADC protein-based immunotherapy work in the body?

ADC protein-based immunotherapy works by using a targeted approach to deliver a potent cytotoxic drug directly to cancer cells while sparing healthy cells. The ADC protein is designed to recognize and bind to specific antigens expressed on the surface of cancer cells. Once bound, the ADC protein is internalized by the cancer cell and the cytotoxic drug is released, causing damage to the cancer cell and eventually leading to cell death.

How effective is ADC protein-based immunotherapy?

The effectiveness of ADC protein-based immunotherapy can vary depending on the specific type of cancer being treated, the patient's individual cancer profile, and the characteristics of the ADC protein being used. However, some studies have shown significant improvement in overall survival and disease progression in patients treated with ADC protein-based immunotherapy compared to traditional cancer treatments alone. Further research is needed to fully assess the potential of ADC protein-based immunotherapy as a viable treatment option for cancer.

How is ADC protein-based immunotherapy administered?

ADC protein-based immunotherapy is typically administered through an intravenous infusion, meaning that the treatment is delivered directly into the patient's bloodstream. The treatment may be administered on an outpatient basis, or the patient may need to stay in the hospital for monitoring during their initial treatment.

How long does ADC protein-based immunotherapy last?

The duration of ADC protein-based immunotherapy can vary depending on the individual patient and the specific type of ADC protein being used. Some patients may require multiple cycles of treatment over the course of several months or years. The treatment schedule is typically determined based on the patient's response to treatment and the likelihood of disease recurrence.

What are the potential side effects of ADC protein-based immunotherapy?

ADC protein-based immunotherapy may cause a range of side effects, including fever, chills, fatigue, nausea, vomiting, and diarrhea. More serious side effects may include heart problems, liver damage, and bleeding disorders. However, the specific side effects of ADC protein-based immunotherapy can vary depending on the individual patient and the specific type of ADC protein being used.

Can ADC protein-based immunotherapy be used in combination with other cancer treatments?

Yes, ADC protein-based immunotherapy can be used in combination with other cancer treatments such as chemotherapy and radiation therapy. Combination therapy can potentially produce better treatment outcomes than monotherapy alone.

How is the ADC protein designed and developed?

The ADC protein is typically designed using a combination of monoclonal antibodies and cytotoxic agents. The monoclonal antibody portion of the ADC protein is engineered to recognize and bind to specific antigens expressed on cancer cells. The cytotoxic agent is then attached to the monoclonal antibody using a chemical linker. The design and development of an ADC protein involves a complex process of selecting the appropriate monoclonal antibody and cytotoxic agent, optimizing the chemical linker, and conducting preclinical studies to assess safety and efficacy.

How is ADC protein administered to patients?

ADC protein-based immunotherapy is usually administered through intravenous infusion. The dosage and treatment schedule will vary depending on the specific type of ADC protein being used and the patient's individual cancer treatment plan.

What types of cancer can be treated with ADC protein-based immunotherapy?

ADC protein-based immunotherapy has been studied in a variety of cancer types, including breast cancer, lung cancer, ovarian cancer, and Hodgkin's lymphoma. The specific type of ADC protein used may vary depending on the type and stage of cancer.

Is ADC protein-based immunotherapy used as a standalone treatment or in combination with other treatments?

ADC protein-based immunotherapy is often used in combination with other cancer treatments, such as chemotherapy or radiation therapy. The combination treatment approach may help to enhance the effectiveness of ADC protein-based immunotherapy.

What are the potential side effects of ADC protein-based immunotherapy?

The side effects of ADC protein-based immunotherapy can vary depending on the specific type of ADC protein being used and the individual patient. Some common side effects include infusion related reactions such as fever, chills, and nausea. More serious side effects can include damage to healthy cells and tissues, nerve damage, and low blood cell counts. Patients should be closely monitored for any adverse reactions and treated accordingly.

What types of cancer can ADC protein-based immunotherapy be used to treat?

ADC protein-based immunotherapy can potentially be used to treat a variety of cancers, as long as there are specific targets or antigens expressed on the surface of cancer cells that can be targeted by the ADC protein. Some examples of cancers that have been successfully treated with ADC protein-based immunotherapy include breast cancer, lung cancer, and lymphoma.